series-a
Stage
2020
Founded
2
Investors
About
Myricx Bio is a biotech company headquartered in London focused on discovering and developing a novel class of antibody-drug conjugates (ADCs) based on N-myristoyltransferase (NMT) inhibition for the treatment of cancer.
Explore Myricx Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.